EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR) Stock Fundamental Analysis
Europe - Euronext Brussels - EBR:ALEMS - BE0974497290 - Common Stock
4.7505 EUR
-0.32 (-6.28%)
Taking everything into account, ALEMS scores 3 out of 10 in our fundamental rating. ALEMS was compared to 86 industry peers in the Biotechnology industry. ALEMS has a medium profitability rating, but doesn't score so well on its financial health evaluation. ALEMS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year ALEMS was profitable.
- In the past year ALEMS had a positive cash flow from operations.
- ALEMS had negative earnings in 4 of the past 5 years.
- The reported operating cash flow has been mixed in the past 5 years: ALEMS reported negative operating cash flow in multiple years.
1.2 Ratios
- ALEMS has a Return On Assets of 2.24%. This is amongst the best in the industry. ALEMS outperforms 80.23% of its industry peers.
- The Return On Equity of ALEMS (10.45%) is better than 84.88% of its industry peers.
- ALEMS has a Return On Invested Capital of 4.79%. This is in the better half of the industry: ALEMS outperforms 77.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.24% | ||
| ROE | 10.45% | ||
| ROIC | 4.79% |
ROA(3y)-7.51%
ROA(5y)-9.94%
ROE(3y)-29.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ALEMS has a better Profit Margin (2.50%) than 75.58% of its industry peers.
- ALEMS has a Operating Margin of 4.12%. This is in the better half of the industry: ALEMS outperforms 74.42% of its industry peers.
- ALEMS's Operating Margin has improved in the last couple of years.
- ALEMS has a Gross Margin of 21.27%. This is comparable to the rest of the industry: ALEMS outperforms 40.70% of its industry peers.
- ALEMS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.12% | ||
| PM (TTM) | 2.5% | ||
| GM | 21.27% |
OM growth 3Y226.24%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ALEMS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for ALEMS has been reduced compared to 1 year ago.
- The number of shares outstanding for ALEMS has been increased compared to 5 years ago.
- ALEMS has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -0.93, we must say that ALEMS is in the distress zone and has some risk of bankruptcy.
- ALEMS's Altman-Z score of -0.93 is in line compared to the rest of the industry. ALEMS outperforms 40.70% of its industry peers.
- ALEMS has a Debt/Equity ratio of 1.22. This is a high value indicating a heavy dependency on external financing.
- ALEMS has a Debt to Equity ratio of 1.22. This is comparable to the rest of the industry: ALEMS outperforms 43.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.93 |
ROIC/WACC0.82
WACC5.87%
2.3 Liquidity
- A Current Ratio of 1.40 indicates that ALEMS should not have too much problems paying its short term obligations.
- The Current ratio of ALEMS (1.40) is worse than 62.79% of its industry peers.
- A Quick Ratio of 0.87 indicates that ALEMS may have some problems paying its short term obligations.
- ALEMS's Quick ratio of 0.87 is on the low side compared to the rest of the industry. ALEMS is outperformed by 68.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 4876.36% over the past year.
- The Revenue has grown by 12.39% in the past year. This is quite good.
- Measured over the past years, ALEMS shows a small growth in Revenue. The Revenue has been growing by 7.56% on average per year.
EPS 1Y (TTM)4876.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%173.33%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y7.56%
Revenue growth 5YN/A
Sales Q2Q%7.52%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 17.59, the valuation of ALEMS can be described as rather expensive.
- Based on the Price/Earnings ratio, ALEMS is valued cheaper than 84.88% of the companies in the same industry.
- ALEMS's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.32.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.59 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, ALEMS is valued cheaply inside the industry as 91.86% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.62 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- ALEMS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EBR:ALEMS (1/22/2026, 7:00:00 PM)
4.7505
-0.32 (-6.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-15 2025-10-15
Earnings (Next)04-13 2026-04-13
Inst Owners0.02%
Inst Owner ChangeN/A
Ins Owners1.2%
Ins Owner ChangeN/A
Market Cap20.09M
Revenue(TTM)46.78M
Net Income(TTM)1.17M
Analysts34.29
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.59 | ||
| Fwd PE | N/A | ||
| P/S | 0.43 | ||
| P/FCF | N/A | ||
| P/OCF | 8.99 | ||
| P/B | 1.8 | ||
| P/tB | 25.09 | ||
| EV/EBITDA | 7.62 |
EPS(TTM)0.27
EY5.68%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)0.53
OCFY11.12%
SpS11.06
BVpS2.64
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Graham Number4.01
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.24% | ||
| ROE | 10.45% | ||
| ROCE | 7.61% | ||
| ROIC | 4.79% | ||
| ROICexc | 5.47% | ||
| ROICexgc | 9.18% | ||
| OM | 4.12% | ||
| PM (TTM) | 2.5% | ||
| GM | 21.27% | ||
| FCFM | N/A |
ROA(3y)-7.51%
ROA(5y)-9.94%
ROE(3y)-29.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y196.37%
ROICexgc growth 5YN/A
ROICexc growth 3Y199.14%
ROICexc growth 5YN/A
OM growth 3Y226.24%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5YN/A
F-Score6
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 3.27 | ||
| Cap/Depr | 136.82% | ||
| Cap/Sales | 6.57% | ||
| Interest Coverage | 2.43 | ||
| Cash Conversion | 53.51% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.4 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | -0.93 |
F-Score6
WACC5.87%
ROIC/WACC0.82
Cap/Depr(3y)97.27%
Cap/Depr(5y)N/A
Cap/Sales(3y)6.88%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4876.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%173.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.39%
Revenue growth 3Y7.56%
Revenue growth 5YN/A
Sales Q2Q%7.52%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y437.83%
EBIT growth 3Y250.9%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y70.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y233.43%
OCF growth 3Y94.38%
OCF growth 5YN/A
EUROPEAN MEDICAL SOLUTIONS S / ALEMS.BR FAQ
What is the fundamental rating for ALEMS stock?
ChartMill assigns a fundamental rating of 3 / 10 to ALEMS.BR.
What is the valuation status for ALEMS stock?
ChartMill assigns a valuation rating of 2 / 10 to EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR). This can be considered as Overvalued.
Can you provide the profitability details for EUROPEAN MEDICAL SOLUTIONS S?
EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR) has a profitability rating of 5 / 10.
Can you provide the financial health for ALEMS stock?
The financial health rating of EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR) is 1 / 10.